Pfizer Stops Swinging For The Fences; Combo Products Are Big Opportunity
Executive Summary
Pfizer is investing more heavily in low-risk "product enhancements" to help round out its R&D portfolio
You may also be interested in...
Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Combination drug products may have more market potential due to their copay advantage, sellside research analysts suggested April 1 at an IIR conference in Philadelphia
Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Combination drug products may have more market potential due to their copay advantage, sellside research analysts suggested April 1 at an IIR conference in Philadelphia
Combo Drug Commercial Potential May Be Lowered By D.C. Court Ruling
A Washington, D.C. federal appeals court ruling could have a significant impact on pharmaceutical companies that are eying combination therapies as growth drivers